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Abstract 
 
There have been substantial strides forward in our understanding of the contribution of regulatory T 
(Treg) cells to cancer immunosuppression. In this issue we present a series of papers highlighting the 
emerging themes on this topic relevant not only to our understanding of the fundamental biology of 
tumour immunosuppression but to the design of new immunotherapeutic approaches. The 
substantially shared biology of CD4+ conventional T (Tconv) and Treg cells necessitates a detailed 
understanding of the often opposing functional consequences that immunotherapies will have on 
Treg and Tconv cells, a prominent example being the potential for Treg-mediated hyperprogressive 
disease following anti-PD-1 therapy. Such understanding will aid patient stratification and the 
rational design of combination therapies. It is now becoming clear that Treg cells within tumours also 
exhibit distinct biological features to both Tconv cells and to Treg cells in other tissues. These distinct 
features provide the opportunity for development of targeted immunotherapies with greater efficacy 
and reduced potential for inducing systemic toxicity.  
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Main text  
T cells have an ability to recognise and kill cancer cells but their function is often suppressed within 
tumours. Whereas CD4+ and CD8+ conventional T (Tconv) cells promote immune activation, CD4+ 
regulatory T (Treg) cells, dependent upon the transcription factor Foxp3, suppress Tconv cell responses 
and are required for immune homeostasis in both mice and humans1, 2. It is now clear however that 
beyond this beneficial function, Treg cells can cause profound suppression of immune function within 
tumours3, 4. In a variety of murine tumour models, ablation of Treg cells results in activation of CD4+ 
or CD8+ Tconv cells and rejection of solid tumours5, 6, 7, 8. Moreover, high Treg ratios relative to total 
T cells or CD8+ Tconv cells are associated with poorer survival in breast cancer9, non-small cell lung 
carcinoma10, hepatocellular carcinoma11, ovarian cancer12, 13, renal cell carcinoma14, pancreatic 
cancer15, colorectal carcinoma16, gastric cancer17 and cervical cancer18. An understanding of a 
powerful role of Treg cells in tumour immunosuppression is thus emerging with extensive evidence 
from experimental mouse models complemented by a growing body of evidence in human cancer. 
In this Review series, we consider the progress made in our understanding of the mechanisms that 
lead to the accumulation and suppressive function of Treg cells within tumours, the unique properties 
of tumour-infiltrating Treg cells, and our means to selectively target them in cancer. 
 
While their immunosuppressive function make Treg cells are an attractive target for specifically 
directed therapy, it is also important to consider the effects upon Treg cells of conventional 
immunotherapies thought to primarily target Tconv cells. Despite striking efficacy in some cases, 
therapies targeting PD-1/PD-L1 signaling are ineffective at inducing durable responses in a majority 
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of patients, and can induce rapidly progressive disease referred to as ‘hyperprogression’ in a 
minority of patients19, 20. A recent study suggests that hyperprogression is in part attributable to 
blockade of PD-1 signaling on Treg cells which, in susceptible individuals, results in enhanced Treg 
suppressive function21. It remains to be determined whether a similar phenomenon underlies poor 
clinical responses to PD-1 therapy in subsets of patients but the findings highlight the need to 
consider the opposing effects that immunotherapies may have on the Tconv and Treg compartments. 
Indeed, such consideration may provide a basis for patient stratification or the rational design of 
combination immunotherapy. Evidence from both mouse models22 and human cancer patients23 
indicate that the activity of anti-CTLA-4 therapy is in part attributable to antibody-dependent 
cellular cytotoxicity (ADCC)-mediated depletion of intratumoural Treg cells, which express high 
levels of CTLA-4. Indeed, in patients with advanced melanoma, favourable response to treatment 
with the anti-CTLA4 monoclonal antibody ipilimumab was associated, among patients with 
inflamed tumours, with the presence of a coding polymorphism within CD16a/FcγRIIIa which 
results in its higher affinity for Fc suggesting that FcγRIIIa-dependent ADCC activity is involved in 
the efficacy of ipilimumab therapy in humans23. As Lim et al. point out, Treg and Teff cells have 
substantially shared intracellular signaling pathways and the balance to which distinct 
immunomodulatory agents affect Treg suppression versus Teff cell-mediated anti-tumour immunity 
determines their net effect upon tumour progression as is exemplified by the net immunostimulatory 
effect of genetic or pharmacological disruption of PI3K activity24. Indeed, it is likely that shared 
expression of CD25 and CCR4 on tumour-infiltrating Treg cells and activated Tconv cells have 
contributed to the lack of robust clinical efficacy of antibody reagents targeting these molecules. 
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Finally, as discussed by Yano et al., checkpoint immunotherapy may result in reactive recruitment 
of Treg cells to tumours in response to increased inflammation25. Thus, a theme emerging from a 
number of reviews in this series is the substantially shared biology of Treg and Tconv cells and the 
need to consider the effects of therapy on both the Treg and Tconv compartments. 
  
Treg cell frequency in the tumour immune infiltrate often far exceeds that in normal tissues, 
suggesting that co-option of Treg cells by tumours is an important feature of cancer development and 
a requisite for cancer progression in number of tumour types. Stockis et al. consider the mechanisms 
that drive Treg accumulation within tumours, reviewing our understanding of the molecular basis for 
recruitment and maintenance of Treg cells within tumours, and proposing that selective recruitment 
of thymic Treg (tTreg) cells rather than de novo induction of induced Treg (iTreg) cells is the dominant 
mechanism by which Treg cells accumulate in cancer26. While experimental observations supportive 
of this conclusion are presented, the relative functional contribution of tTreg and iTreg cells to tumour 
immunosuppression has yet to be formally established. Treg cells within tumours express high levels 
of specific chemokine receptors, such as CCR2, CCR4, CCR8 and CCR10, and it is plausible, 
though again not clearly established, that expression of these receptors drive recruitment of Treg 
cells into tumours. In addition, the association of tumours with tertiary lymphoid structures 
contributes to recruitment of Treg cells into tumours27. The tumour environment provides an 
environment supportive of Treg cell proliferation and Stockis et al., also review the role of co-
stimulatory and co-inhibitory receptor and cytokine signaling on Treg cell maintenance and activation 
in tumours. It is clear, however, that much more work is needed to better dissect the distinct functions 
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of chemokine, cytokine and co-stimulatory/co-inhibitory receptors on Treg and Tconv cell migration 
and function, respectively. 
 
Given the shared involvement of Treg cells in immunological tolerance and tumour 
immunosuppression, selective targeting of Treg cells in tumours is desirable but requires an 
understanding of their specific biological characteristics. Yano et al. consider the specific molecular 
and functional characteristics of Treg cells in tumours, observing that a number of molecular, cellular 
and metabolic characteristics distinguish them from Treg cells in other tissues25. Morena Ayala et al. 
describe attempts made to target the immunosuppressive function of Treg cells in preclinical mouse 
tumour models and in the clinic27. Such attempts include systemic administration of P300/HAT, 
EZH2 and BET inhibitors whose consequence upon Treg cell suppression results in augmented 
tumour immunity. Zaiss et al. review the role of tissue-resident Treg cells in promoting both non-
immune processes and immune processes associated with wound healing. In part, this activity is 
mediated by release of the EGF-like growth factor Amphiregulin by Treg cells whose activity 
extends beyond its canonical function in wound repair to promoting the release of bioactive TGF- 
through inside-out activation of integrins. The extent to which the function of Treg-derived Areg in 
promoting tumour immunosuppression involves canonical and non-canonical Areg functions have 
yet to be determined28.  
 
In summary, there have been substantial strides in our understanding of the contribution of Treg cells 
to tumour immunosuppression. A detailed understanding of the often opposing effects of 
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immunotherapies on both the Tconv and Treg compartments will aid the design of new immunotherapy 
approaches and the interpretation of their outcomes. In addition, there is a growing awareness of the 
involvement of Treg cells in influencing the outcome conventional checkpoint inhibitor therapy 
responses, with potential functional contributions as profound and deleterious as anti-PD-1-induced 
hyperprogression. In this context, the shared biology of Treg and Tconv cells presents both an 
obstacle and an opportunity, especially for patient stratification and rational design of combination 
immunotherapies. The observation that Treg cells in tumours harbour distinct molecular profiles that 
contribute to their selective migration and function and that distinguish them from Treg cells in other 
tissues provide extremely important opportunities for the selective targeting of Treg cells in cancer.   
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